{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:49:46Z","timestamp":1794620986865,"version":"4.9.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To further characterize the effect of guselkumab, a selective IL-23p19-subunit inhibitor approved for PsA, on enthesitis and assess relationships between enthesitis resolution and patient status\/outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with active PsA despite standard therapies in the phase 3 DISCOVER-1 and DISCOVER-2 studies were randomized 1:1:1 to guselkumab 100\u2009mg every 4\u2009weeks (Q4W); guselkumab 100\u2009mg at week 0, week 4, Q8W; or placebo through week 20 followed by guselkumab 100\u2009mg Q4W. Independent assessors evaluated enthesitis using the Leeds Enthesitis Index (LEI; total score 0\u20136). Enthesitis findings through week 24 were pre-specified to be pooled across studies; post hoc and week 52 analyses also employed pooled data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1118 randomized, treated patients in DISCOVER-1 and 2 who had \u22651 LEI site evaluated, 65% had enthesitis at baseline. These patients exhibited numerically more swollen and tender joints, systemic inflammation and impaired physical function than patients without enthesitis. Guselkumab Q4W and Q8W were superior to placebo in resolving pre-existing enthesitis at week 24 (45 and 50% vs 29%; both adjusted P\u2009=\u20090.0301). Enthesitis resolution rates continued to rise; 58% of guselkumab-randomized patients achieved resolution at week 52, including patients with mild (LEI\u2009=\u20091; 70\u201375%), moderate (LEI\u2009=\u20092; 69\u201373%) or severe (LEI\u2009=\u20093\u20136; 42\u201344%) enthesitis at baseline. Among guselkumab-randomized patients with resolved enthesitis at week 24, 42% achieved minimal disease activity at week 52, vs 17% of patients with unresolved enthesitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Guselkumab resulted in higher proportions of PsA patients with resolved enthesitis by week 24, with maintenance of resolution rates through 1\u2009year. As enthesitis confers greater disease burden, sustained resolution could portend better patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>DISCOVER 1 (NCT03162796) and DISCOVER 2 (NCT03158285)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab285","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T15:19:15Z","timestamp":1617635955000},"page":"5337-5350","source":"Crossref","is-referenced-by-count":35,"title":["Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7715-8226","authenticated-orcid":false,"given":"Dennis","family":"McGonagle","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Leeds Biomedical Research Centre, University of Leeds, Leeds"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oregon Health & Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[{"name":"Internal Medicine 3, FAU Erlangen-Nuremburg and Universitatsklinikum, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Shawi","sequence":"additional","affiliation":[{"name":"Department of Immunology, Janssen Global Services"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Kafka","sequence":"additional","affiliation":[{"name":"Department of Immunology, Janssen Scientific Affairs, LLC, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan S","family":"Karyekar","sequence":"additional","affiliation":[{"name":"Department of Immunology, Janssen Global Services"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa P","family":"Kollmeier","sequence":"additional","affiliation":[{"name":"Department of Immunology, Janssen Research & Development, LLC, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C","family":"Hsia","sequence":"additional","affiliation":[{"name":"Department of Immunology, Janssen Research & Development, LLC, Spring House"},{"name":"Department of Rheumatology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xie L","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Janssen Research & Development, LLC, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihong","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Clinical Biostatistics, Janssen Research & Development, LLC, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasheen","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Clinical Biostatistics, Janssen Research & Development, LLC, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Clinical Biostatistics, Janssen Research & Development, LLC, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T","family":"Ritchlin","sequence":"additional","affiliation":[{"name":"Allergy\/Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Memorial University of Newfoundland, St Johns, NL, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Swedish Medical Center\/Providence, St Joseph Health and University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,6]]},"reference":[{"key":"2021110402575322200_keab285-B1","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados","year":"2011","journal-title":"Lancet"},{"key":"2021110402575322200_keab285-B2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3899\/jrheum.180797","article-title":"Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: a systematic review and metaanalysis","volume":"47","author":"Mourad","year":"2020","journal-title":"J Rheumatol"},{"key":"2021110402575322200_keab285-B3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2017.12.008","article-title":"Enthesitis: a hallmark of psoriatic arthritis","volume":"48","author":"Kaeley","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2021110402575322200_keab285-B4","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021110402575322200_keab285-B5","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/acr.23174","article-title":"Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: incidence, prevalence, characteristics, and outcome","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021110402575322200_keab285-B6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021110402575322200_keab285-B7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jbspin.2009.09.011","article-title":"Psoriatic arthritis: correlation between imaging and pathology","volume":"77","author":"Tan","year":"2010","journal-title":"Joint Bone Spine"},{"key":"2021110402575322200_keab285-B8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13075-019-1831-0","article-title":"Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis","volume":"21","author":"Gladman","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2021110402575322200_keab285-B9","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021110402575322200_keab285-B10","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021110402575322200_keab285-B11","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.39732","article-title":"Interleukin-23-dependent \u03b3\/\u03b4 T cells produce interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice","volume":"68","author":"Reinhardt","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021110402575322200_keab285-B12","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4\u2212CD8\u2212 entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"2021110402575322200_keab285-B13","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/annrheumdis-2018-214944","article-title":"Identification of myeloid cells in the human enthesis as the main source of local IL-23 production","volume":"78","author":"Bridgewood","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021110402575322200_keab285-B14","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","article-title":"Evidence that tissue resident human enthesis \u03b3\u03b4T-cells can produce IL-17A independently of IL-23R transcript expression","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021110402575322200_keab285-B15","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-218151","article-title":"Is a human in vitro enthesitis model relevant to SpA-associated enthesitis? Response to: \u2018Beware of wolves in sheep\u2019s clothing: immune cell plasticity and instability in health and disease' by Alunno et al","author":"Watad","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021110402575322200_keab285-B16","volume-title":"Tremfya: package insert","year":"2020"},{"key":"2021110402575322200_keab285-B17","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFa inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"2021110402575322200_keab285-B18","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"2021110402575322200_keab285-B19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.41553","article-title":"Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through 1 year in biologic-na\u00efve psoriatic arthritis patients","volume":"73","author":"McInnes","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2021110402575322200_keab285-B20","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1136\/annrheumdis-2020-eular.842","article-title":"Guselkumab, an inhibitor of the IL-23p19-subunit, provided sustained improvement in signs and symptoms of active psoriatic arthritis: one year results of a phase 3 randomized study of patients who were biologic-na\u00efve or TNF\u03b1 inhibitor-experienced","volume":"79","author":"Ritchlin","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021110402575322200_keab285-B21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.23568","article-title":"Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis","volume":"59","author":"Healy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021110402575322200_keab285-B22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021110402575322200_keab285-B23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-3083.2009.03363.x","article-title":"Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease","volume":"23 (Suppl 1","author":"McGonagle","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021110402575322200_keab285-B24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/art.39458","article-title":"Review: Enthesitis: new insights into pathogenesis, diagnostic modalities, and treatment","volume":"68","author":"Kehl","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021110402575322200_keab285-B25","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/1756-185X.12505","article-title":"Sleep quality in patients with psoriatic arthritis","volume":"20","author":"Gezer","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2021110402575322200_keab285-B26","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/acr.23249","article-title":"Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"69","author":"Mease","year":"2017","journal-title":"Arthritis Care Res (Hoboken"},{"key":"2021110402575322200_keab285-B27","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","article-title":"Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study","volume":"48","author":"Araujo","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2021110402575322200_keab285-B28","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13075-019-2055-z","article-title":"Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies","volume":"21","author":"Coates","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2021110402575322200_keab285-B29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/imr.12840","article-title":"Interleukin-23 pathway at the enthesis: the emerging story of enthesitis in spondyloarthropathy","volume":"294","author":"Bridgewood","year":"2020","journal-title":"Immunol Rev"},{"key":"2021110402575322200_keab285-B30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41584-018-0091-8","article-title":"Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis","volume":"14","author":"Gravallese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2021110402575322200_keab285-B31","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2021110402575322200_keab285-B32","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"2021110402575322200_keab285-B33","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","article-title":"Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021110402575322200_keab285-B34","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"2021110402575322200_keab285-B35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021110402575322200_keab285-B36","first-page":"ii14","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2021110402575322200_keab285-B37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13075-017-1265-5","article-title":"Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis","volume":"19","author":"Bergman","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2021110402575322200_keab285-B38","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3899\/jrheum.130949","article-title":"Is the MAdrid Sonographic Enthesitis Index useful for differentiating psoriatic arthritis from psoriasis alone and healthy controls?","volume":"41","author":"Eder","year":"2014","journal-title":"J Rheumatol"},{"key":"2021110402575322200_keab285-B39","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2021110402575322200_keab285-B40","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab285\/39919329\/keab285.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/11\/5337\/41073249\/keab285.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/11\/5337\/41073249\/keab285.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T13:40:05Z","timestamp":1698846005000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/11\/5337\/6212041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,4,6]]},"published-print":{"date-parts":[[2021,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab285","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,4,6]]}}}